Dorzolamide/timolol combination has hypotensive and haemodynamic effects

A fixed combination of dorzolamide and timolol significantly increase blood flow at the neuroretinal rim, demonstrating a combination of hypotensive and haemodynamic effects.

A fixed combination of dorzolamide and timolol significantly increase blood flow at the neuroretinal rim, demonstrating a combination of hypotensive and haemodynamic effects, according to a report published online ahead of print by Eye.

Teresa Rolle and colleagues from the University of Torino, Italy compared the effect of dorzolamide hydrochloride 2%, timolol maleate 0.5% and their fixed combination on intraocular pressure (IOP) and retinal and optic nerve head haemodynamics in 28 patients with primary open angle glaucoma.

After a four-week wash-out period, patients were randomized into two groups: group 1 received dorzolamide 2% monotherapy and group 2 received timolol 0.5% monotherapy. Following this period, both groups switched to a fixed combination of the two drugs for four-weeks. IOP, ocular diastolic perfusion pressure (ODPP), heart rate and scanning laser Doppler flowmetry measurements at the peripapillary retina and neuroretinal rim were taken at enrolment (T0), wash-out (T1), during monotherapy (T3) and during combination therapy (T4).

At T1 and T3, IOP had decreased significantly in group 1 (p<0.001) and in group 2 (p<0.001). At the same intervals, blood flow increased significantly at rim level in group 1 (p<0.05). Between intervals of T1 and T3, a significant increase in ODPP was observed in both groups.

The authors of this study believe that a fixed combination of dorzolamide and timolol significantly increases blood flow at the neuroretinal rim.

Related Videos
Disrupting the glaucoma treatment paradigm with novel femtosecond laser from ViaLase
2-year data in contralateral eye evaluation gives edge to iStent inject over Hydrus stent
Should endocyclophotocoagulation be considered part of MIGS? Mr Ratnarajan delves in
Investigating the effects of canaloplasty on corneal epithelium
© 2023 MJH Life Sciences

All rights reserved.